Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30‐week, double‐blind, phase 3a, randomized trial

AIM: To evaluate the efficacy and safety of once‐weekly subcutaneous semaglutide, a glucagon‐like peptide‐1 (GLP‐1) analogue, versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes (T2D) in a multiregional clinical trial. MATERIALS AND METHODS: In the 30‐week, randomiz...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Diabetes Obes Metab
Asıl Yazarlar: Ji, Linong, Dong, Xiaolin, Li, Yiming, Li, Yufeng, Lim, Soo, Liu, Ming, Ning, Zu, Rasmussen, Søren, Skjøth, Trine Vang, Yuan, Guoyue, Eliaschewitz, Freddy G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Blackwell Publishing Ltd 2021
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7839591/
https://ncbi.nlm.nih.gov/pubmed/33074557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14232
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller